XML 139 R124.htm IDEA: XBRL DOCUMENT v3.25.0.1
Quarterly Results of Operations (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Quarterly Financial Data [Abstract]                      
Revenue $ 646,542 $ 621,401 $ 647,145 $ 639,653 $ 556,055 $ 511,015 $ 469,136 $ 427,690 $ 2,554,741 [1] $ 1,963,896 [1] $ 1,352,013 [1]
Total operating expenses 665,138 637,669 639,357 653,062 577,405 528,953 490,704 438,045 2,595,226 2,035,107 1,348,371
Loss before preferred dividends and accretion of Series A Preferred Stock (22,802) (23,137) 1,596 (17,280) (33,411) (25,324) (34,323) (19,982) (61,623) (113,040) (19,164)
Dividends and accretion of Series A Preferred Stock (7,813) (8,094) (7,979) (7,945) (7,984) (7,872) (7,088) (6,276) (31,831) (29,220) 0
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (30,615) (31,231) (6,383) (25,225) (41,395) (33,196) (41,411) (26,258) (93,454) (142,260) (19,164)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (30,615) $ (31,231) $ (6,383) $ (25,225) $ (41,395) $ (33,196) $ (41,411) $ (26,258) $ (93,454) $ (142,260) $ (19,164)
Loss per common share                      
Basic (in dollars per share) $ (0.27) $ (0.27) $ (0.06) $ (0.22) $ (0.36) $ (0.30) $ (0.37) $ (0.24) $ (0.81) $ (1.28) $ (0.20)
Diluted (in dollars per share) $ (0.27) $ (0.27) $ (0.06) $ (0.22) $ (0.36) $ (0.30) $ (0.37) $ (0.24) $ (0.81) $ (1.28) $ (0.20)
[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.